{"protocolSection": {"identificationModule": {"nctId": "NCT03772041", "orgStudyIdInfo": {"id": "263-102-00003"}, "secondaryIdInfos": [{"id": "JapicCTI-184234", "type": "OTHER", "domain": "Japic"}], "organization": {"fullName": "Otsuka Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure", "officialTitle": "A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group, Non-inferiority Trial to Evaluate the Efficacy and Safety of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure"}, "statusModule": {"statusVerifiedDate": "2021-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-01-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-07-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-07-29", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-12-05", "studyFirstSubmitQcDate": "2018-12-10", "studyFirstPostDateStruct": {"date": "2018-12-11", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-07-14", "resultsFirstSubmitQcDate": "2021-07-14", "resultsFirstPostDateStruct": {"date": "2021-08-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-07-14", "lastUpdatePostDateStruct": {"date": "2021-08-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Otsuka Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To confirm the non-inferiority of OPC-61815 16-mg injection to tolvaptan 15-mg tablet using as the primary endpoint the change in body weight following 5-day intravenous administration of OPC-61815 16-mg injection or 5-day oral administration of tolvaptan 15-mg tablet to CHF patients with volume overload despite having received diuretics other than vasopressin antagonists"}, "conditionsModule": {"conditions": ["Congestive Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 294, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "OPC-61815 injection 16 mg", "type": "EXPERIMENTAL", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg", "interventionNames": ["Drug: OPC-61815"]}, {"label": "Tolvaptan tablet 15mg", "type": "ACTIVE_COMPARATOR", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo", "interventionNames": ["Drug: Tolvaptan Tab 15 MG"]}], "interventions": [{"type": "DRUG", "name": "OPC-61815", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg", "armGroupLabels": ["OPC-61815 injection 16 mg"]}, {"type": "DRUG", "name": "Tolvaptan Tab 15 MG", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo", "armGroupLabels": ["Tolvaptan tablet 15mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Body Weight", "description": "Change in body weight from baseline (before investigational medicinal product \\[IMP\\] administration on Day 1) at time of final IMP administration (day after final IMP administration). A negative change from baseline indicates improvement.", "timeFrame": "Baseline, Day 6"}], "secondaryOutcomes": [{"measure": "Improvement Rate for Lower Limb Edema and Pulmonary Congestion", "description": "The improvement rate was defined as the percentage of subjects in whom the symptom was present at baseline and it markedly improved or improved after IMP administration. Improvement category is a 4-point scale below:\n\n* Markedly improved\n* Improved\n* Unchanged\n* Deteriorated", "timeFrame": "Baseline, Day 6"}, {"measure": "Change From Baseline in Jugular Venous Distension and Hepatomegaly", "description": "* Jugular Venous Distension: the presence of Jugular Venous Distension was checked, and if present, the height (in cm) from the sternal angle to the highest point of pulsation in the internal Jugular vein was measured with the subject in a semi-upright position. A negative change from baseline indicates improvement.\n* Hepatomegaly: the presence of a palpable liver was checked, and if present, the width (distance from the right costal arch of the right chest, in cm) was measured. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, Day 6"}, {"measure": "Percentage of Subjects Who Achieve Resolution of Pulmonary Rales and Third Cardiac Sound", "description": "Percentage of subjects in whom the symptom was present at baseline and disappeared after IMP administration was provided.\n\n* The presence of pulmonary rales was checked by auscultation.\n* The presence of cardiac third sound was checked by auscultation.", "timeFrame": "Baseline, Day 6"}, {"measure": "Improvement Rate for New York Heart Association (NYHA) Classification", "description": "NYHA classification assesses the severity of heart failure based on subjective symptoms as follows.\n\nClass I: No limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or anginal pain.\n\nClass II: Slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or anginal pain.\n\nClass III: Marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or anginal pain.\n\nClass IV: Inability to carry on any physical activity without discomfort. heart failure or anginal syndrome may have been present even at rest. If any physical activity was undertaken, discomfort was increased.\n\nOf the subjects with Class II or higher at baseline, the percentage of subjects whose NYHA classification stage at the time of final IMP administration improved by 1 or more grades was provided.", "timeFrame": "Baseline, Day 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who are currently on treatment with any of the following diuretics\n\n  1. Loop diuretics equivalent to furosemide tablet or fine granules at a dose of 40 mg/day or higher\n  2. Concomitant use of a loop diuretic and a thiazide diuretic (including thiazide analogs) at any dose\n  3. Concomitant use of a loop diuretic and an aldosterone antagonist or potassium-sparing diuretic agent at any dose\n* Patients with congestive heart failure in whom lower limb edema, pulmonary congestion, and/or jugular venous distension due to volume overload is present\n* Patients who are currently hospitalized or who are able to be hospitalized during the trial\n\nExclusion Criteria:\n\n* Patients with acute heart failure\n* Patients who are on a ventricular assist device\n* Patients who are unable to sense thirst or who have difficulty with fluid intake", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Osamu Sato", "affiliation": "Otsuka Pharmaceutical Co., Ltd.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Saiseikai Kumamoto Hospital", "city": "Kumamoto", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.", "timeFrame": "Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.", "accessCriteria": "Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to https://clinical-trials.otsuka.com/contact-us", "url": "https://clinical-trials.otsuka.com/contact-us"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "OPC-61815 Injection 16 mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "FG001", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "149"}, {"groupId": "FG001", "numSubjects": "145"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "135"}, {"groupId": "FG001", "numSubjects": "135"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "10"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "OPC-61815 Injection 16 mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "BG001", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "149"}, {"groupId": "BG001", "value": "145"}, {"groupId": "BG002", "value": "294"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74.0", "spread": "10.2"}, {"groupId": "BG001", "value": "75.4", "spread": "8.2"}, {"groupId": "BG002", "value": "74.7", "spread": "9.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "84"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "112"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "210"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "149"}, {"groupId": "BG001", "value": "145"}, {"groupId": "BG002", "value": "294"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "149"}, {"groupId": "BG001", "value": "145"}, {"groupId": "BG002", "value": "294"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Body Weight", "description": "Change in body weight from baseline (before investigational medicinal product \\[IMP\\] administration on Day 1) at time of final IMP administration (day after final IMP administration). A negative change from baseline indicates improvement.", "populationDescription": "Full Analysis Set: subjects who received at least one dose of IMP and had at least one postbaseline weight measurement", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline, Day 6", "groups": [{"id": "OG000", "title": "OPC-61815 Injection 16 mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "OG001", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.67", "lowerLimit": "-1.93", "upperLimit": "-1.41"}, {"groupId": "OG001", "value": "-1.36", "lowerLimit": "-1.62", "upperLimit": "-1.10"}]}]}]}, {"type": "SECONDARY", "title": "Improvement Rate for Lower Limb Edema and Pulmonary Congestion", "description": "The improvement rate was defined as the percentage of subjects in whom the symptom was present at baseline and it markedly improved or improved after IMP administration. Improvement category is a 4-point scale below:\n\n* Markedly improved\n* Improved\n* Unchanged\n* Deteriorated", "populationDescription": "Full Analysis Set: subjects who received at least one dose of IMP and had at least one postbaseline weight measurement were included in the full analysis. \"Number Analyzed\" = number of subjects with baseline symptoms.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Day 6", "groups": [{"id": "OG000", "title": "OPC-61815 Injection 16 mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "OG001", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "145"}]}], "classes": [{"title": "Lower Limb Edema", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "111"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "68.9"}, {"groupId": "OG001", "value": "75.7"}]}]}, {"title": "Pulmonary Congestion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}, {"groupId": "OG001", "value": "119"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "56.1"}, {"groupId": "OG001", "value": "64.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Jugular Venous Distension and Hepatomegaly", "description": "* Jugular Venous Distension: the presence of Jugular Venous Distension was checked, and if present, the height (in cm) from the sternal angle to the highest point of pulsation in the internal Jugular vein was measured with the subject in a semi-upright position. A negative change from baseline indicates improvement.\n* Hepatomegaly: the presence of a palpable liver was checked, and if present, the width (distance from the right costal arch of the right chest, in cm) was measured. A negative change from baseline indicates improvement.", "populationDescription": "Subjects with baseline values in the Full Analysis Set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "cm", "timeFrame": "Baseline, Day 6", "groups": [{"id": "OG000", "title": "OPC-61815 Injection 16 mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "OG001", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "145"}]}], "classes": [{"title": "Jugular Venous Distension", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "59"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.89", "lowerLimit": "-3.45", "upperLimit": "-2.33"}, {"groupId": "OG001", "value": "-3.15", "lowerLimit": "-3.68", "upperLimit": "-2.62"}]}]}, {"title": "Hepatomegaly", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.93", "lowerLimit": "-1.44", "upperLimit": "-0.43"}, {"groupId": "OG001", "value": "-0.88", "lowerLimit": "-1.43", "upperLimit": "-0.33"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Subjects Who Achieve Resolution of Pulmonary Rales and Third Cardiac Sound", "description": "Percentage of subjects in whom the symptom was present at baseline and disappeared after IMP administration was provided.\n\n* The presence of pulmonary rales was checked by auscultation.\n* The presence of cardiac third sound was checked by auscultation.", "populationDescription": "Full Analysis Set: subjects who received at least one dose of IMP and had at least one postbaseline weight measurement were included in the full analysis. \"Number Analyzed\" = number of subjects with baseline symptoms.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Day 6", "groups": [{"id": "OG000", "title": "OPC-61815 Injection 16 mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "OG001", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "145"}]}], "classes": [{"title": "Pulmonary Rales", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "74.3"}, {"groupId": "OG001", "value": "78.9"}]}]}, {"title": "Third Cardiac Sound", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "31.7"}, {"groupId": "OG001", "value": "31.0"}]}]}]}, {"type": "SECONDARY", "title": "Improvement Rate for New York Heart Association (NYHA) Classification", "description": "NYHA classification assesses the severity of heart failure based on subjective symptoms as follows.\n\nClass I: No limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or anginal pain.\n\nClass II: Slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or anginal pain.\n\nClass III: Marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or anginal pain.\n\nClass IV: Inability to carry on any physical activity without discomfort. heart failure or anginal syndrome may have been present even at rest. If any physical activity was undertaken, discomfort was increased.\n\nOf the subjects with Class II or higher at baseline, the percentage of subjects whose NYHA classification stage at the time of final IMP administration improved by 1 or more grades was provided.", "populationDescription": "Full Analysis Set: subjects who received at least one dose of IMP and had at least one postbaseline weight measurement were included in the full analysis. \"Overall Number of Participants Analyzed\" = number of subjects with a baseline of class II or more.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Day 6", "groups": [{"id": "OG000", "title": "OPC-61815 Injection 16 mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "OG001", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44.9"}, {"groupId": "OG001", "value": "42.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Treatment-emergent adverse events (TEAEs) were collected from the start of IMP administration up to 15 days", "description": "Subjects who received at least one dose of IMP were included in the safety analysis.", "eventGroups": [{"id": "EG000", "title": "OPC-61815 Injection 16 mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.", "deathsNumAffected": 0, "deathsNumAtRisk": 149, "seriousNumAffected": 6, "seriousNumAtRisk": 149, "otherNumAffected": 61, "otherNumAtRisk": 149}, {"id": "EG001", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.", "deathsNumAffected": 0, "deathsNumAtRisk": 145, "seriousNumAffected": 5, "seriousNumAtRisk": 145, "otherNumAffected": 57, "otherNumAtRisk": 145}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Sinus node dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Gastric antral vascular ectasia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}]}, {"term": "General infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 145}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 145}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 145}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 145}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 145}]}, {"term": "Thirst", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 145}]}, {"term": "Blood potassium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 145}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 145}]}, {"term": "Hypernatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 145}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 145}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 145}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Ver. 23.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 145}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Director of Clinical Trials", "organization": "Otsuka Pharmaceutical Co., LTD.", "email": "CL_OPCJ_RDA_Team@otsuka.jp", "phone": "+81-3-6361-7366"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-03-27", "uploadDate": "2021-07-08T21:40", "filename": "Prot_000.pdf", "size": 936559}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-09-14", "uploadDate": "2021-07-08T21:42", "filename": "SAP_001.pdf", "size": 1875189}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Congestive Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077602", "term": "Tolvaptan"}], "ancestors": [{"id": "D000065092", "term": "Antidiuretic Hormone Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M1858", "name": "Tolvaptan", "asFound": "Total volume", "relevance": "HIGH"}, {"id": "M17414", "name": "Vasopressins", "relevance": "LOW"}, {"id": "M4437", "name": "Arginine Vasopressin", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Coag", "name": "Coagulants"}]}}, "hasResults": true}